Anzeige
Mehr »
Dienstag, 12.05.2026 - Börsentäglich über 12.000 News
Kann Inspiration Mining die nächste 1.000 % Chance werden? Das Bohrprogramm startet in wenigen Tagen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41E9H | ISIN: US6960776010 | Ticker-Symbol:
NASDAQ
11.05.26 | 22:00
19,330 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PALATIN TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
PALATIN TECHNOLOGIES INC 5-Tage-Chart

Aktuelle News zur PALATIN TECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.03.Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings1.187HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening...
► Artikel lesen
PALATIN TECHNOLOGIES Aktie jetzt für 0€ handeln
17.02.PALATIN TECHNOLOGIES INC - 10-Q, Quarterly Report49
17.02.Palatin Technologies GAAP EPS of -$2.86 misses by $0.51, revenue of $0.11M beats by $0.09M30
17.02.Palatin Technologies, Inc.: Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update613Advancing differentiated MC4R-based obesity programs into clinical development Melanocortin-based obesity therapies targeting rare MC4R pathway disorders with...
► Artikel lesen
12.12.25Laidlaw initiates coverage on Palatin Technologies stock with Buy rating94
11.12.25Why Are Palatin Technologies (PTN) Shares Spiking After-Hours?69
13.11.25Palatin Technologies: Umsatzsprung im ersten Quartal, Aktie gibt dennoch nach172
13.11.25Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update972Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement...
► Artikel lesen
12.11.25Palatin Technologies, Inc.: Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option700Trading of Palatin's common shares resumed trading on NYSE today, November 12, 2025, under the symbol "PTN" PRINCETON, N.J., Nov. 12, 2025 /PRNewswire/ -- Palatin...
► Artikel lesen
06.11.25Palatin Technologies, Inc.: Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering346$15.8 million at closing with up to an additional $15.8 million upon the cash exercise of the milestone related warrants Regains compliance with NYSE American...
► Artikel lesen
22.09.25Palatin Technologies, Inc.: Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim621Collaboration focused on developing potential first-in-class melanocortin receptor targeted treatment for patients with diabetic retinopathy, including diabetic...
► Artikel lesen
18.08.25Boehringer Ingelheim Limited: Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases1.236· Collaboration strengthens Boehringer's pipeline in Eye Health.· Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an...
► Artikel lesen
08.08.25Palatin Technologies, Inc.: Palatin Announces 1-for-50 Reverse Stock Split959PRINCETON, N.J., Aug. 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), today announced a reverse stock split ("Reverse Stock Split") of its...
► Artikel lesen
15.07.25Palatin Technologies, Inc.: Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity1.036Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment Combination of oral PL7737 and tirzepatide resulted in additive...
► Artikel lesen
14.05.25Palatin Technologies Q1 Net Loss Narrows On Lower Expenses1.355WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin...
► Artikel lesen
14.05.25Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update672Significant Progress in Obesity and Ocular Programs Teleconference and Webcast to be held today - May 14, 2025, at 11:00 AM EST CRANBURY, N.J., May 14, 2025...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,870